title: Disrupted foveal photoreceptors after combined cystoid spaces and retinal detachment in branch vein occlusion treated with bevacizumab.
abstract: OBJECTIVE
  To investigate how combined cystoid spaces and serous retinal detachment affect photoreceptor status and visual acuity at final visit in macular edema associated with branch retinal vein occlusion.
  
  
  METHODS
  Forty-seven consecutive eyes from 47 patients with macular edema associated with branch retinal vein occlusion treated with intravitreal bevacizumab injection were retrospectively reviewed. Foveal pathomorphology on optical coherence tomography images were divided into two groups: those in which combined foveal cystoid spaces and serous retinal detachment were observed at least once (C+S(+)) and those in which they were not observed (C+S(-)). The relationship between foveal pathomorphology and photoreceptor status and logarithm of the minimum angle of resolution at final visit was investigated.
  
  
  RESULTS
  Sixteen eyes were categorized as C+S(+), and the final visual acuity of C+S(+) group was significantly worse than that of C+S(-) group compared with no difference at baseline. Intriguingly, combined foveal pathomorphologies during the course were significantly associated with the absence of external limiting membrane and the junction of inner and outer segments at last visit. Using multivariable analysis, final logarithm of the minimum angle of resolution was significantly related to baseline logarithm of the minimum angle of resolution, diabetes, and C+S(+).
  
  
  CONCLUSIONS
  Combined foveal cystoid spaces and retinal detachment during follow-up predict the disrupted foveal photoreceptors and concomitant poor final visual acuity in branch retinal vein occlusion treated with intravitreal bevacizumab injection.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan. mutomo@kuhp.kyoto-u.ac.jp
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Murakami
authors.forename: Akitaka
authors.initials: A
authors.lastname: Tsujikawa
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Miyamoto
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sakamoto
authors.forename: Ken
authors.initials: K
authors.lastname: Ogino
authors.forename: Yuki
authors.initials: Y
authors.lastname: Muraoka
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Kurashige
authors.forename: Nagahisa
authors.initials: N
authors.lastname: Yoshimura
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D005260:Female; D005584:Fovea Centralis / Q000473:pathology*; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D008297:Male; D020419:Photoreceptor Cells, Vertebrate / Q000473:pathology*; D012163:Retinal Detachment / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab